AstraZeneca (AZN) Pharmaceuticals surovatamig was granted FDA orphan designation as a treatment of acute lymphocytic leukemia, according to a post to the agency’s website.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- IonQ Secures DARPA Stage B Slot, Maps Quantum Road to 2033
- AstraZeneca announces baxdrostat met primary endpoint in Bax24 Phase III trial
- IonQ and D-Wave Q3 Earnings Results Set the Pace Ahead of Rigetti and Quantum Computing Inc.
- AstraZeneca’s Earnings Call Highlights Strong Growth and Future Ambitions
- Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed